Bone Evaluation in HIV-positive women over 40 who Switch from TDF + 3TC/FTC + NNRTI to Triumeq

Trial Profile

Bone Evaluation in HIV-positive women over 40 who Switch from TDF + 3TC/FTC + NNRTI to Triumeq

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Etravirine; Lamivudine; Nevirapine; Rilpivirine; Tenofovir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms BESTT women's
  • Most Recent Events

    • 14 Jul 2016 Planned End Date changed from 11 Jul 2019 to 29 Mar 2018.
    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top